A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?

Sponsor
GOG

Protocol Number
GOG-0225

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Sponsor
ECOG-ACRIN

Protocol Number
EAY131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

Molecular Analysis for Therapy Choice (MATCH)

Type of Cancer
Gynecologic

Sponsor
ECOG-ACRIN

Protocol Number
EAY 131 MATCH (CIRB)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Sponsor
Tesaro

Protocol Number
PR-30-5020-C QUADRA

To Learn More Call
201-510-0910

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910

Feasibility and Clinical Significance of Sentinel Lymph Node Dissection in Endometrial Cancer Staging

Sponsor
HackensackUMC

Protocol Number
Pro00006051

To Learn More Call
201-510-0910